Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SERA PROGNOSTICS, INC.

(SERA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sera Prognostics, Inc. Announces Unaudited Earnings Results for the third Quarter and nine Months Ended September 30, 2021

11/09/2021 | 04:01pm EST

Sera Prognostics, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2021. For the quarter, the company announced revenue of $23,000 compared to $5,000 a year ago. Loss from operations was $9,442,000 compared to $4,644,000 a year ago. Net loss and comprehensive loss was $9,859,000 or $0.39 per basic and diluted share compared to $5,072,000 or $3.30 per basic and diluted share a year ago. For the nine months, the company announced revenue of $56,000 compared to $19,000 a year ago. Loss from operations was $22,848,000 compared to $13,217,000 a year ago. Net loss and comprehensive loss was $22,525,000 or $2.32 per basic and diluted share compared to $14,473,000 or $9.46 per basic and diluted share a year ago.


ę S&P Capital IQ 2021
All news about SERA PROGNOSTICS, INC.
01/10Certain Class B Common Stock of Sera Prognostics, Inc. are subject to a Lock-Up Agreeme..
CI
01/10Certain Class A Common Stock of Sera Prognostics, Inc. are subject to a Lock-Up Agreeme..
CI
01/10Certain Stock Options of Sera Prognostics, Inc. are subject to a Lock-Up Agreement End..
CI
01/10Certain Warrants of Sera Prognostics, Inc. are subject to a Lock-Up Agreement Ending on..
CI
2021SERA PROGNOSTICS, INC.(NASDAQGM : SERA) added to NASDAQ Biotechnology Index
CI
2021Sera Prognostics to Join Nasdaq Biotechnology Index
MT
2021Sera prognostics added to nasdaq biotechnology index
PR
2021Sera Prognostics Inc. Announces Pricing for PreTRM? Test, the Only Broadly Validated Bl..
CI
2021Sera Prognostics Says Study Confirms Performance of Its Biomarkers to Address Preterm B..
MT
2021Sera Prognostics Announces Publication Of Data Confirming The Performance Of The IBP4/S..
PR
More news
Analyst Recommendations on SERA PROGNOSTICS, INC.
More recommendations
Financials (USD)
Sales 2021 0,19 M - -
Net income 2021 -31,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,26x
Yield 2021 -
Capitalization 211 M 211 M -
Capi. / Sales 2021 1 094x
Capi. / Sales 2022 31,5x
Nbr of Employees 73
Free-Float 85,0%
Chart SERA PROGNOSTICS, INC.
Duration : Period :
Sera Prognostics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 6,88 $
Average target price 18,50 $
Spread / Average Target 169%
EPS Revisions
Managers and Directors
Gregory C. Critchfield Chairman, President & Chief Executive Officer
Jay M. Moyes Chief Financial Officer
John J. Boniface Chief Scientific Officer
Thomas J. Garite Vice President-Clinical Sciences
Robert Gardner Harrison Chief Information Officer